Deadline: Various

Contact
Olga Hog

+49‐30‐81 45 06‐10

Links Read full call

Calll for Papers

The European Pharmaceutical Law Review (EPLR) provides a forum to discuss, comment and review all issues raised by the development and implementation of the law and policy governing the area of pharmaceutical law in the EU Member States in law and practice.

Content and Form

Contributors to the journal report on key legislative developments in the EU and the Member States, and identify and analyse important judgments that shape the interpretation and application of EU pharmaceutical law, in particular those by the European Courts, international courts and tribunals such as the WTO's Dispute Settlement Body, and higher national courts. For the issues of EPLR in 2017, we welcome submissions of articles, country or policy reports and case annotations on, but not limited to, the following topics:

  • Pharmaceutical law and policy in all jurisdictions (regional, national, international);

  • Commission decisions (EMA opinions) and regulatory guidelines;

  • National EU, and International Jurisprudence;

  • Medical devices;

  • Borderline cases: pharmaceuticals/food/cosmetics/chemicals

  • Patents /Trademarks;

  • Health Technology Assessment and pricing/reimbursement

  • Digital health/Big data

All contributions will be subject to double blind peer‐review before acceptance for publication and are required to conform to the author guidelines available at: www.lexxion.eu/eplr/author‐guidelines

Deadlines for Submissions

  • Issue 1/2017:   24.4.2017

  • Issue 2/2017:   28.7.2017

  • Issue 3/2017:   10.11.2017

Contributions may be submitted after the published deadlines, by arrangement with the editor. All submissions should be in British English and conform to the OSCOLA style of referencing.

Contact

The editorial team looks forward to discussing your proposals and receiving your submissions. For further enquiries, please contact the Executive Editor:

Olga Hog
hog@lexxion.de
+49‐30‐81 45 06‐10 

bioethics biotechnology health law policy opportunity pharmaceuticals